Immunomonitoring of Interventional Radiology Procedures in the Management of Hepatocellular Carcinoma

NCT ID: NCT04892810

Last Updated: 2021-05-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-05-31

Study Completion Date

2022-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This cohort study compares immune response induced in two groups of small HCC patients treated by ablation (group1 RFA, group 2 MWA). Patients will benefit for tumoral and non tumoral biopsies prior to treatment and stepped peripheral blood samples juste before ablation and during the first month after.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatocellular Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

RFA

Patient with HCC and decision of treatment with ablation

Percutaneous ablation

Intervention Type PROCEDURE

Hepatic Percutaneous Ablation with radiofrequency or microwave

MWA

Patient with HCC and decision of treatment with ablation

Percutaneous ablation

Intervention Type PROCEDURE

Hepatic Percutaneous Ablation with radiofrequency or microwave

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Percutaneous ablation

Hepatic Percutaneous Ablation with radiofrequency or microwave

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically proven HCC for less than 3 months before ablation
* Decision of ablation treatment in multidisciplinary meeting

Exclusion Criteria

* Fibrolamellar HCC
* Hepatocholangiocarcinoma
Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Grenoble

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Julien GUELFI, PH

Role: CONTACT

04 76 76 89 09

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Grenoble University Hospital

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Ga-68 Dolacga PET Scan in HCC Under RFA
NCT06792097 NOT_YET_RECRUITING